In the evening of the same day, Xia Yu convened all the members of the acquisition team to summarize today's results and agree on tomorrow's plan according to the situation.

As soon as I came up, I would like to report on the current situation of each group.

Needless to say, Xia Yu's group won all of them that day.

Peter Lynch's second group was in charge of York Capital.

He reported to Xia Yu: "Chairman, today we negotiated with the CEO of York Capital for a day, and they have agreed to sell the shares, and now the difficulty is that the price cannot be negotiated. ”

York Capital offered $55 million, but the negotiations were terminated due to time constraints. ”

Xia Yu bowed slightly, and looked at Brandon Gus, the leader of the third group, who immediately said: "Chairman, Kongston Capital has a lot of confidence in Genentech and has refused to sell its equity until the afternoon, when we persuaded them to agree to sell its equity, but they offered a very high price, asking for $21.5 million for 8.6% of the equity!"

At this price, it can be seen that their valuation of Genentech is $250 million, which is $50 million higher than the valuation of Colele Perkins!

But Xia Yu also expressed his understanding, because at the beginning, he expected that Constance Capital's attitude towards selling its stake would be the most negative.

After all, they joined after defeating a large number of opponents in the third round of funding, and they are destined to have the most confidence in Genentech.

And the latest to enter means that their appetite will be the greatest, and they also have the capital strength to take this risk, and they have the strength to wait for Genentech to go public.

Unlike the Colelle Perkins Company, which has weak capital strength and has never seen the big world, Xia Yu made them obediently raise and surrender when he bid higher.

After motioning for Brandon Gus to sit down, Xia Yu said with a smile: "Actually, the situation is not bad, although it was not successful that day, but both of your groups successfully persuaded them to sell their shares, the difference is only in the price." ”

"York Capital valued Genentech at $220 million, Conston Capital at $250 million, and Colelle Perkins, which I was responsible for, was valued at $200 million, which is a bit of a big difference. ”

"But it doesn't matter, Constance Capital has the lowest shareholding ratio, even if the valuation is high, it will be one or two million dollars more, promise them!"

"You can tell them the price of the Corelle Perkins Company today, and use it to drive down the price!"

"I just have one request, tomorrow, the acquisition must be completed, this is the company's first action, I don't want accidents! I hope you can perform well!"

Everyone's hearts sank, and they agreed in unison.

Then, continue to discuss the detailed attack strategy, and strive to let York Capital and Constance Capital follow the rhythm of Polaris Capital tomorrow!

......

Early the next morning, Peter Lynch, Brandon Guss and others set out again.

And Xia Yu took his subordinates and others to Genentech.

He hadn't forgotten that Professor Herb Boyle wanted to see him.

And the stake in Professor Herb Boyle's hands is also something he covets.

Xia Yu waited in the reception room for less than five minutes before he saw an old man in his fifties wearing glasses walk in.

Xia Yu saw the photo and immediately recognized it, this person was Professor Herb Boyle.

He immediately got up and greeted with a little respect: "Hello, Professor Herb Boyle, I am the chairman of Polaris Capital, my name is Xia Yu, you can call me Xia." ”

Professor Herb Boyle was not domineering, he smiled, shook hands with Xia Yu, called Xia Yu's name a little awkwardly, and said, "Hello, Mr. Xia!

"Thank you, please take a seat!"

After taking their seats one after another, Professor Herb Boyle asked bluntly: "Mr. Xia, Robert Swanson told me yesterday that the equity of their company has been sold to you, and you have agreed to my conditions, and now we are facing each other, I want to know what is the purpose of your acquisition of Genentech? What is your attitude?"

It is worthy of being engaged in scientific research, and speaking is straightforward, but this kind of character is just right, there are not so many flower intestines, as long as you touch the right door, you will actually get along very well.

Xia Yu said with a smile: "Professor Herb Boyle, the reason why we acquired Genentech is because we are very optimistic about you, and we believe that your research can benefit the world, so we are willing to help you promote your research results to the world, and get some remuneration in the process." ”

Xia Yu's words are very artistic, even if Professor Herb Boyle doesn't like people to pat on the back, the corners of his mouth are slightly raised, his face has eased a lot, and he is much closer to Xia Yu.

Professor Herb Boyle squeezed out a smile and said, "Mr. Xia, if you really have this attitude, then I welcome you!"

Xia Yu nodded immediately, and the scene was very bright: "Of course, we will fully support your research." ”

"By the way, Professor Herb Boyle, we are very optimistic about you, so in addition to acquiring the stake in Colayler Perkins, we are also acquiring the stakes in York Capital and Conston Capital. ”

In a few simple words, Xia Yu already knew what kind of essence Professor Herb Boyle was, so in order to avoid misunderstanding, he made things clear.

Professor Herb Boyle really didn't know the news, he frowned, stared at Xia Yu, and said bluntly: "If you acquire the equity of the two companies, then the listing process of Genentech will be terminated, but my scientific research and patent production will require a lot of money!"

Xia Yu looked at him calmly, and immediately said: "This is not a problem, Professor Herb Boyle, no matter how much capital you need, we at Polaris Capital can inject capital!

After speaking, in order to dispel Professor Herb Boyle's doubts, Xia Yu also changed his train of thought and said: "Professor Herb Boyle, in fact, you should know that there are advantages to the company's listing, but there are also disadvantages, if Genentech encounters difficulties in the future, the stock market will transmit huge pressure to you, your plans will be subject to stricter approval, and the media spotlight will always shine on you, so that you can't conduct scientific research with peace of mind!"

Xia Yu's words are very reasonable, and Professor Herb Boyle has also learned about the advantages and disadvantages of the stock market in his spare time, and naturally he is also aware of past cases.

"As far as I know, Genentech went public because the next research and expansion requires a large amount of money, and now we can afford this money, I hope you can avoid being disturbed by the hustle and bustle of the outside world, and we will do our best to create a better research environment for you." ”

Professor Herb Boyle was able to win the Nobel Prize, and he was naturally an experimental, and if it weren't for the huge amount of money needed for the next expansion, the three limelight companies might not be able to afford it, and he would not have been instigated to agree to the company's application for listing.

At present, only two of his scientific research results have been released, and both are still under approval, and have not yet been put into production, and the risk still exists.

Since Xia Yu's Polaris Capital is willing to take over the baton, he also hopes to be able to study quietly.

As for the dilution of his equity after the capital injection of Polaris Capital, he does not care, he is not keen on money, and even he has the idea of setting up a scientific research fund with his assets after his death to support the research of latecomers in the field of DNA.

There is a lot of chance in his success, but not every time a goddess of luck strikes, so he doesn't want those who come after him to also struggle to find the truth because of the difficult scientific research conditions.

"Mr. Xia, welcome to join us!"

Professor Herb Boyle said with a smile.

"Professor Herb Boyle, thank you, I believe we will get along very happily in the future!" Xia Yu said with a smile, shaking hands with him again.

Professor Herb Boyle smiled and nodded, "I hope so!"

"Now the company's funds are no longer enough, and when you finish the acquisition, I hope you can inject funds as soon as possible!"

"No problem, if we can close the acquisition today, then we can inject capital at any time, everything depends on your wishes!"

......

Xia Yu had a very pleasant chat with Professor Herb Boyle, but the latter thought about his experiment, and after resolving his doubts, he took his leave and hurried back to the laboratory.

In the afternoon of the same day, the acquisitions of both groups were completed.

Among them, Peter Lynch took out the case of Colayler Perkins, and the psychological defense of York Capital Company collapsed at once, and finally transferred 25% of the equity held by him at a price of 51 million US dollars.

Brandon Gus, on the other hand, also used all his resources to compress Genentech's valuation to $220 million.

As a result, the transfer price of the 8.6 percent stake held by Constance Capital is $18.92 million.

So far, Polaris Capital has spent a total of $119.92 million to acquire 58.6% of the shares, becoming the largest shareholder of Genentech.

At this price, Xia Yu was very satisfied.

According to the historical trajectory, on the day of Genentech's listing, the stock price of Genentech rose from $35 to the highest $88, and even the closing price exceeded $70, and the market value directly reached $300 million.

Now half a year ahead of schedule, the valuation of Genentech is controlled at more than $200 million, which is also very cost-effective.

Of course, if you take into account the future market value of Genentech's 100 billion yuan, it will be even more worthwhile!

After the completion of the acquisition, Xia Yu immediately approached Professor Herb Boyle to discuss capital injection.

In order to leave a good impression, Xia Yu was not too harsh, valuing the current Genentech company at $210 million.

And in order to win as much equity as possible, Xia Yu constantly encouraged him to develop by leaps and bounds, buy newer and better experimental instruments, build a top laboratory, and directly build a large factory from the perspective of Professor Herb Boyle.

In short, how to spend money and how to come, is to take advantage of this rare opportunity to obtain equity as much as possible.

If you don't seize the opportunity to do it this time, you won't know that the next time it's going to be the Year of the Monkey, and the cost will be extremely scary by then!

Professor Herb Boyle was coaxed red by Xia Yu and felt very good about Xia Yu.

In the end, a huge expansion plan was made, and it was decided to inject 50 million US dollars into the company at one time!

After the capital injection, Xia Yu's equity ratio increased by 19.23%.

The total shareholding ratio increased to 77.83%.

Professor Herb Boyle's shareholding has dropped from 41.4 percent to 22.17 percent!

At this point, Xia Yu can officially announce!

Genentech, the hunt is a success!

()